CytoMed Therapeutics Ltd (GDTC) Price Prediction & ForecastGDTCForecastCytoMed Therapeutics Ltd

Alphio's GDTC stock price prediction model matches the current CytoMed Therapeutics Ltd tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $0.99 (+7.67%). The 1-week path is $0.99 (+7.77%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

CytoMed Therapeutics Ltd (GDTC) is not a good buy right now due to its significant downward trends and poor financial metrics. The current price is $0.92, which is down 33.81% year-to-date and 54.11% over the past year. Additionally, the stock has a negative P/E ratio of -1.91 and a forward P/E of 0, indicating a lack of profitability and future earnings potential. The RSI is at 46.19, suggesting the stock is neither overbought nor oversold, but the overall trend is negative. The main risk is the 5-day change of -10.68%, indicating a recent sharp decline in value.

CytoMed Therapeutics Ltd (GDTC) last closed at $0.92, losing -3.16%. These facts feed the 1-day and 1-week GDTC price prediction above.